Animal disease models have been criticized for lack of resemblance to human illnesses, hampering transfer of knowledge from preclinical research to clinical medicine. In the field of allogeneic hematopoietic stem cell transplantation (allo-HSCT), it is standard practice to study GVHD in lethal TBI-based murine models. Frequently, MHC-mismatched donors are used in GVHD models. In contrast, in clinical allo-HSCT conditioning with chemotherapy (+/ − TBI) is common and donors are often MHC-matched. Aiming at a more clinically oriented situation, we established and characterized a murine MHC-matched, minor histocompatibility antigen mismatched GVHD model (LP/J [H2k b ] → C57BL/6 [H2k b ]) using busulfan and cyclophosphamide conditioning. We found typical clinical and histological features of acute GVHD. T-cell infiltration, GVHD-specific damage and systemic inflammation were similar to observations made in patients after allo-HSCT. In survivors of acute GVHD, we found expansion of CD4+ T cells and the development of scleroderma-like chronic GVHD. The use of chemotherapy-based, minor histocompatibility antigen (miHA)-mismatched GVHD animal models may be a good option when studying clinically relevant questions in the field of allo-HSCT.
INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) is an important curative therapy for malignant and non-malignant hematological disorders. However, beneficial effects of the therapy are limited by GVHD, one of the major complications after HSCT. Allogeneic T cells contained in the transplant specifically attack the recipient organs intestine, liver and skin, leading to substantial morbidity and mortality. The majority of our knowledge about the biology of this systemic inflammatory disease has developed from preclinical inbred mouse models; 1 however, mechanisms underlying the development, progression and effective treatment of GVHD are still not fully understood.
To amend our fundamental knowledge of this disease and to develop new treatment strategies, accurate and clinically relevant experimental GVHD models are needed. Van der Worp et al. 2 raised the concern about animal experiments for predicting effectiveness of treatment strategies if critical disparities between experimental and clinical features of the disease exist. This results in a failure to translate promising results in animal models to the clinic in a sufficient way. 2 Also in the field of transplantation biology, many findings from mouse models failed to correlate with the clinical scenario. Examples of significant distinctions from the clinical setting in the historically established mouse models are (1) the exclusive use of lethal TBI as conditioning and (2) MHC mismatches. 3, 4 In murine GVHD studies, high-dose TBI is typically used without cytotoxic drugs, although this is no standard procedure in the clinical setting. 5 In contrast, the majority of patients undergoing HSCTs under current conditions receive TBI-free chemotherapy conditioning with drugs, such as busulfan, cyclophosphamide, fludarabine, thiotepa, melphalan or treosulfan. 6 For experimental GVHD, mouse strain combinations are mainly used with immunologic disparity in MHC antigens between the donor and the recipient 5 leading to a strong immunologic response. Again in contrast, in the clinical setting the great majority of transplants are performed using HLA-matched, or only partially mismatched donors.
In the present study, we established and characterized a murine GVHD model that is based on chemotherapy conditioning and has differences in minor histocompatibility antigens (miHAs) as opposed to MHC antigens. Bone marrow transplantation Recipient C57BL/6 mice were injected IV with 1.5 × 10 7 bone marrow (BM) cells and 2 × 10 6 splenic T cells from LP/J or 129S2/SvPasCrl (allogeneic) and C57BL/6 (syngeneic) donor mice on d0. BM was flushed from tibia and femur, and single-cell suspension was prepared in PBS/2% FCS/1 mM EDTA by gently passing through a 23G needle and over a 70-μm cell strainer (BD Biosciences, San Jose, CA, USA). Erythrocytes were lysed with ammonium chloride (Sigma-Aldrich), and BM cells were washed two times. Splenic T-cell suspension was obtained using a Pan T cell isolation Kit II for mouse (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. Sample size for bone marrow transplantation (BMT) experiments was calculated by Statistics Facility. Animals were randomized including equal distribution of weight status and mixed housing of different transplanted animals. For subsequent analyses, transplant conditions were encoded.
MATERIALS AND METHODS Mice

GVHD monitoring
Mice were individually scored twice a week for five clinical parameters (posture, activity, fur, skin and weight loss) on a scale from 0 to 2 (Supplementary Table S1 ). Clinical GVHD score was assessed by summation of these parameters. Survival was monitored daily. GVHD experiments were performed with at least five mice per group.
Hematological analysis
Blood from the facial vein was collected in MiniCollect EDTA tubes (Greiner Bio-one, Kremsmünster, Austria), and hematological parameters were recorded on a Coulter AcT8 Hematology analyser (Beckman Coulter, Brea, CA, USA). (No. of Exp. = 2; syn: N = 10, allo: N = 19).
FACS analysis
Single-cell suspensions of blood, BM, spleen and thymus were prepared. Splenocytes and thymocytes were passed through a 40-μm cell strainer. Erythrocytes were lysed with ammonium chloride. Cells were washed twice and stained for 20 min at 4°C in PBS/0.5 mM EDTA/0.5% BSA with the following rat mAbs from BD Biosciences: anti-Ly9.1 (30C7-PE), anti-CD62L (MEL14-PE), anti-CD8a (53-6.7-APC), anti-Ly-6G and Ly6C/Gr1 (RB6-8C5-APC), anti-CD69 (H1.2F3-APC), anti-CD45R/B220 (RA3-6B2-PerCP-Cy5.5), anti-NK1.1 (PK136-PerCP-Cy5.5), anti-CD25 (PC61-PerCP-Cy5.5), anti-H2kb (AF6-88.5-FITC), anti-CD4 (RM4-5-PE-Cy7), anti-CD11c (HL3-PE-Cy7), anti-CD3e (145-2C11-APC-Cy7) and anti-CD11b (M1/70-APC-Cy7). For regulatory T-cell staining, Anti-Mouse/Rat FoxP3 Staining Set APC (eBioscience, San Diego, CA, USA) was used following the manufacturer's instructions. Samples were analyzed by BD FACSCanto II (BD Biosciences) and FlowJo 7.6.5 Software (TreeStar Inc., Ashland, OR, USA) (thymus, T regs, BM and spleen-No. of Exp. = 2; N = 5 per group, blood-No. of Exp. = 3; N = 10 per group).
Histology
Tissue samples were cryoembedded in Tissue-tek optimum cutting temperature compound (Sakura Finetek, Alphen aan den Rijn, The Netherlands). In all, 7 μm sections were acetone-fixed (−20°C) and blinded for transplant conditions. Histopathological score was assessed on H&E-stained sections by S Elezkurtaj after Lerner criteria 7 and grade of liver inflammation (slight (1) or marked (2) portal/venous and marked lobular (3) inflammation). Detection of CD4 and CD8 was performed using rat mAbs, H129.19 and 53-6.7 (BD Biosciences), respectively. Briefly, sections were blocked with PBS/3% BSA/5% FCS and stained overnight at 4°C with primary antibodies. For visualization, secondary donkey anti-rat antibody conjugated with Alexa Fluor 488 (Life Technologies, Carlsbad, CA, USA) and nuclear counterstaining with 4',6-diamidino-2-phenylindole (Sigma-Aldrich) were used. Five sections per sample were investigated with a BA410 epifluorescence microscope (Motic, Causeway Bay, Hong Kong), and CD4+/CD8+ area to total area was quantified with a predetermined threshold using Fiji Software 
Statistics
Survival data were analyzed using the Kaplan-Meier method and Mantel-Cox log-rank test. For all other data, the two-sided unpaired t-test was used. Normality tests and F test confirmed Gaussian distribution and equality of variance between different groups. Values are presented as mean ± s.e.m., P ⩽ 0.05 is considered as statistically significant. All statistical analyses were performed using the GraphPad Prism software (GraphPad Software Inc., La Jolla, CA, USA).
RESULTS
Chemotherapy conditioning and transplantation
Donor and recipient mice were chosen for H2-identity and differed only in multiple minor histocompatibility loci. 8 Dose optimization of chemotherapy conditioning revealed suitable concentrations of busulfan (20 mg/kg/day) and cyclophosphamide (100 mg/kg/day) for recipient mice. Mice treated with an increased dose of cyclophosphamide (200 mg/kg/day) died within 5 days after transplantation, whereas decrease of busulfan (15 mg/kg/day) led to only mild GVHD symptoms. Addition of fludarabine (0.5 mg/kg/day) for 3 days did not change the effects of either regimen. Appropriate conditioned and allogeneic-transplanted C57BL/6 mice ( Figure 1a ) showed stable donor chimerism in blood and BM already at d+15 with 83% donor specific expression of Ly9.1 cell-surface glycoprotein (Figure 1b) . Transplanted mice showed a conditioning-related decrease in hemoglobin, WBC and platelet counts early after transplantation. WBC and platelets increased significantly at d+11 in allogeneic-transplanted animals synchronized with the onset of clinical GVHD symptoms. At d+24, WBC dropped down to naive levels while platelets counts during GVHD were lower as compared with controls ( Figure 1c ).
Clinical GVHD manifestations
Significantly decreased survival was observed in allogeneictransplanted mice (Figure 2a) . A strong decline in survival was seen at the zenith of clinical GVHD scoring around d+20. Weight loss is a reliable indicator of acute GVHD in mice. 9 All transplanted animals regained weight after BMT; however, allogeneictransplanted mice started to lose weight around d+15 and reached the nadir at d+20 (syn: 110.8 ± 1.4% vs allo: 97.4 ± 4.0%; P = 0.005) (Figure 2b ). Weight loss coincided with rising GVHD scores starting at d+10 and a significant increase at the zenith around d+20 (syn: 2.6 ± 0.11% vs allo: 5.06 ± 0.45%; P o 0.0001) in allogeneic-transplanted mice (Figure 2c ). In detail, mice showed low activity, a hunched posture, a loss of fur combined with severe scurf on those hair free areas and overall poor condition ( Figure 2d ). In our mouse model, acute GVHD phase manifests from d+10 to d+25 with highest GVHD scoring, decreased survival and increased weight loss in allogeneic-transplanted mice. We confirmed the results in another chemotherapy-based, miHAmismatched allo-HSCT model (129S2/SvPasCrl → C57BL/6), which showed high similarities in GVHD progression (Supplementary Figure S1 ). Between d+15 and +25 after BMT, weight loss of allogeneic-transplanted animals was significant compared with control animals. (c) GVHD score after BMT. Allogeneic-transplanted animals showed significant increased GVHD score compared with control animals. Animals were regularly scored for five clinical parameters (weight loss, posture, activity, fur and skin) on a scale from 0 to 2. Clinical GVHD score was generated by summation of these five parameters. (d) Phenotype of allogeneic-and syngeneic-transplanted mice. Control animals showed no abnormalities in fur and skin, whereas in GVHD animals loss of fur and scurf (white arrows) occurred. Data from one representative of ten independent experiments, N = 10 per group (*P o0.05, **P o0.01, ***Po 0.001). A full color version of this figure is available at the Bone Marrow Transplantation journal online.
Target organ GVHD During the acute GVHD phase (d+15), allogeneic-transplanted mice exhibited histopathological effects of GVHD in target organs ( Figure 3a ) with significant increased histopathological scores in large bowel (syn: 0.75 ± 0.25 vs allo: 2.0 ± 0.31; P = 0.02), liver (syn: 1.0 ± 0.0 vs allo: 3.0 ± 0.0; P o 0.0001) and abdominal skin (syn: 0.0 ± 0.0 vs allo: 2.5 ± 0.28; P = 0.0001) (Figure 3b) . In large bowel, crypt structure was severely disturbed with an increased number of apoptotic bodies, cryptal abscess ('dropping out crypts'), focal necrosis and presence of inflammatory cells. In contrast, syngeneic-transplanted mice displayed near normal structure with few apoptotic cells. In liver, allogeneic-transplanted mice showed abundant periportal infiltration of lymphocytes and, to a lesser extent, neutrophilic granulocytes with extension to the liver lobules. In syngeneic-transplanted mice, infiltration occurred only rarely and remained periportal. Whereas the syngeneic group displayed an intact epidermal and dermal layer with normal morphology (adnexae and sebaceous glands), extensive skin changes occurred in allogeneic-transplanted mice including increased apoptotic figures, mainly localized to hair follicles and inflammatory infiltration. In addition, vacuolization developed at the border of epidermis and dermis with small infiltrates of neutrophilic granulocytes and slight lifting of the epidermal layer. Survivors of acute GVHD developed chronic GVHD at later stages. At d+64 after BMT, liver of allogeneic-transplanted mice exhibited periportal mononuclear infiltrates and periportal fibrosis with beginning of septum formation. In addition, skin of those mice showed fibrosis and atrophy of adnexal structures (Supplementary Figure S2) . Allogeneic-transplanted mice showed significantly reduced numbers of thymocytes at d+15, especially CD4+/CD8+ double-positive thymocytes (Figure 3c ), which is a distinctive hallmark of thymic GVHD. 10 Highly elevated positive areas of CD4 and CD8 staining on tissue sections of large and small bowel, liver and abdominal skin revealed significantly increased number of tissue-infiltrating T cells in allogeneic-transplanted mice (Figure 3d) . Whereas a basal distribution of CD4+ T cells was also detected in syngeneic-transplanted mice, CD8+ T cells only appeared in target organs of allogeneic-transplanted mice, namely around the crypts of the gut mucosal layer and periportal and lobular in the liver (Figure 3e ). In addition, allogeneictransplanted mice showed a significantly elevated mRNA expression level of ST2 in liver and large bowel during acute GVHD phase (Figure 3f ). ST2, a receptor for IL-33 and effector molecule of Th2 responses, is a novel and promising candidate biomarker for acute GVHD identified by proteomics. Increased plasma levels in patients at GVHD therapy initiation correlated with treatment unresponsiveness and higher mortality. 11, 12 Our results show that chemotherapy-treated and MHC-matched allogeneic-transplanted animals developed a strong and characteristic target organ GVHD.
Systemic GVHD Allogeneic-transplanted mice showed a time point-dependent increase in T cells, granulocytes and monocytes and a decrease in B cells and natural killer cells compared with syngeneictransplanted mice (Figure 4a ). CD3+ T cells were elevated in GVHD animals at d+15 and in a later phase (d+52 to d+64), suggesting a two-step inflammatory process (Supplementary Figure S3a) , interestingly CD8+ and CD4+ T-cell subsets specifically dictated the two time peaks. Whereas CD4+ T cells increased at later time points in GVHD animals (d+52; syn: 0.795 ± 0.056 vs allo: 1.296 ± 0.24; P = 0.01), the increase in CD8+ T cells (d+15; syn: 0.028 ± 0.003 vs allo: 0.182 ± 0.024; P o0.0001) was related to the acute GVHD phase. At late phase (d+52 to d+64) T-cell recovery was observed in peripheral blood of transplanted mice along with reconstituted thymopoiesis (Supplementary Table S2 ). In addition, myeloid cells (granulocytes and monocytes) increased at d+15 in allogeneic-transplanted mice, emphasizing the acute immune reaction. A further increase in CD11b+ monocytes in allogeneictransplanted mice in a later phase (d+52) underlines a second later inflammatory peak. A significant decrease in B220+ B cells (d+15; syn: 0.64 ± 0.135 vs allo: 0.059 ± 0.013; P = 0.001) and NK1.1+ natural killer cells (d+15; syn: 0.065 ± 0.014 vs allo: 0.021 ± 0.004; P = 0.01) was detected in the allogeneic-transplanted animals at d+15. We further checked for CD11c+ dendritic cells, but could not detect any significant differences (Supplementary Figure S3a) . Number of lymphatic and myeloid cells were altered in BM and spleen of allogeneic-transplanted mice on d+15 comparable to results obtained in peripheral blood (Supplementary Figures  S3c, d ). Whereas CD4+ T cells did not increase at d+15 in allogeneic animals, CD8+ and CD4+/CD8+ double-positive T cells did significantly in spleen. In addition, Gr1+ granulocyte and CD11b+ monocyte cell numbers were significantly elevated, B220+ B-cell numbers were decreased in GVHD animals in both organs. Our results demonstrate that allogeneic-transplanted mice developed a systemic GVHD with a strong CD8+ T cell-driven acute GVHD phase and a later CD4+ T cell-driven phase.
Regulatory T cells and T-cell activation markers
Regulatory T cells (T regs) are potent suppressors of immune responses and are known to be decreased in acute GVHD, in mouse models as well as in patients, resulting in limited ability to maintain immune homeostasis. 13 We determined percentage and absolute number of T regs in peripheral blood and spleen at d+15 by gating FoxP3+ cells from CD3+CD4+CD25+ fraction using FACS analysis. T regs were significantly decreased in blood of allogeneic-transplanted mice compared with syngeneic control (Figure 4b ), suggesting declined ability of regulating the proinflammatory environment. In spleen, we could not detect significant differences (Figure 4b ). FACS analysis of T-cell activation markers CD62L and CD69 at d+15 in blood, spleen and lymph nodes revealed increased percentage of CD8+CD62L − and CD4+CD62L − T cells, suggesting a switch from a naive to an effector T-cell status, and of CD4+CD69+ T cells showing increased T-cell activation in allogeneic-transplanted mice (Supplementary Figure S3b) .
Cytokines: TNF-α and IFN-γ Many cytokines are involved in the development of acute GVHD and are effective in a cascade during immune cell activation. 14 We analyzed cytokine serum levels in naive C57BL/6, only chemotherapy-treated and in syngeneic-and allogeneictransplanted mice at 4, 8, 11 and 15 days after BMT. Levels of the three main mediators in the GVHD cytokine storm TNF-α, IFN-γ and IL-6 changed in a time-dependent manner (Figure 4c ). In allo-BMT recipients, TNF-α and IFN-γ cytokine levels were significantly increased from d+8 on (Figure 4c) , suggesting a cytokine-driven inflammatory environment. IFN-γ levels peaked at d+8 and declined slightly afterwards. Highest TNF-α levels were recorded on d+11 and coincided with the onset of GVHD symptoms. IL-6 levels increased due to chemotherapy treatment (IL-6; naive: 0.89 ± 0.89 pg/ml vs Chemo: 70.8 ± 7.9 pg/ml; P = 0.01), concluding an inflammatory status due to tissue damage by the conditioning regimen. Whereas IL-6 levels of syngeneic-transplanted mice declined after BMT, the levels showed a tendency to increase in allogeneic-transplanted mice (Figure 4c ). Other inflammatory cytokines, such as IL-2, IL-4 and IL-17A, remained at low levels after BMT and did not show any significant differences between syngeneic-and allogeneic-transplanted mice (Supplementary Figure S3e) . IL-10 levels significantly increased in allogeneictransplanted mice at d+11 (Supplementary Figure S3e) .
DISCUSSION
In the present study, we describe a mouse model that may be advantageous in reflecting the clinical situation of HSCT and GVHD. The clinical pattern and timing of acute GVHD that we observe resembles the clinical situation of HLA-matched allo-HSCT with GVHD prophylaxis and differs from the hyper acute GVHD that is seen in currently used TBI-based MHC-mismatched murine models. [15] [16] [17] The main feature of the herein described GVHD model is the combination of chemotherapy conditioning with MHC-matched (miHA-mismatched) transplantation. Chemotherapy conditioning has been previously described [18] [19] [20] [21] [22] [23] [24] and this work has been the basis for the development of our model. Sadeghi and colleagues [18] [19] [20] successfully established conditioning with busulfan and cyclophosphamide in an MHC-mismatched model (C57BL/6 (H2k b ) → BALB/c (H2k d )). Although our miHAmismatched model exhibits closely comparable clinical and histopathological acute GVHD symptoms and signs of inflammation (for example, increase in CD8+ T cells and decrease in B cells), there are significant differences in the clinical progression of GVHD. We do not observe a hyper acute disease pattern in the first 7 days after HSCT. Of note, our mouse model lacks the biphasic pathogenesis, described by Sadeghi et al. 19 -but not seen in most GVHD patients. Instead, we found a constant progression to acute GVHD, which resembles more closely the clinical setting of HLA-matched allo-HSCT with GVHD prophylaxis. We confirmed these results in another miHA-mismatched allo-HSCT model (129S2/SvPasCrl → C57BL/6) where we found similar GVHD progression. The use of miHA-mismatched allo-HSCT models may be advantageous when studying clinically important questions because of their closer resemblance to the clinical situation.
Various lethal TBI-based MHC-matched mouse models of GVHD with differences in miHAs have been described in the literature (reviewed in Schroeder and DiPersio 3 and Reddy and Ferrara 4 ). Those models show less morbidity than MHC-mismatched models, but still develop lethal GVHD with a specific CD4+ or CD8+ T-cell response depending on particular miHA differences, 3 for example, B10.D2 (H2k d ) → BALB/c or DBA/2 (H2k d ) 25, 26 or LP/J (H2k b ) → C57BL/6 (H2k b ). 27, 28 The use of TBI instead of chemotherapy conditioning in the LP/J → C57BL/6 model results in diverging GVHD pathophysiology, demonstrating the influence of the conditioning regimen on GVHD development. We found that chemotherapy conditioning in this model results in acute GVHD with typical lesions and lymphocyte infiltration in target organs, such as the intestines, liver and skin. In contrast, irradiated C57BL/6 recipients of LP/J BM+T cells lack severe acute GVHD symptoms and later on develop chronic GVHD. 29 Chronic GVHD in the TBI-based model is characterized by inflammatory lesions in skin, lungs, kidneys and eyes. 29 Interestingly, we observed similar scleroderma-like chronic GHVD at later stages in survivors of acute GVHD in the chemotherapy-based model.
Currently, the majority of acute GVHD mouse models are TBI based, which has several advantages: (1) in small animals, the administration of TBI is faster and easier as compared with the administration of chemotherapy; (2) sustained engraftment with full donor chimerism can be easily achieved and (3) TBI-based models produce reliably GVHD and are well characterized. However, the use of lethal TBI without chemotherapy in mouse models contrasts the standard procedure in clinical allo-HSCT. In the last decade, chemotherapy conditioning has been increasingly used. Nowadays, the great majority of allo-HSCT is performed by using chemotherapy without irradiation as conditioning therapy.
It is not a standard procedure to perform myeloablative conditioning exclusively with TBI (without chemotherapy) in clinical allo-HSCT. To address this difference between clinical allo-HSCT and preclinical models, we developed a chemotherapybased miHA-mismatched allo-HSCT model. In our view, a chemotherapy-based miHA-mismatched allo-HSCT model is theoretically superior to the currently used TBI-based murine models with regard to the clinical significance of the obtained results. Whether these theoretical advantages result in a better translation of the preclinical results remains an open question.
In patients, the skin is most commonly the first affected organ during GVHD, characterized by a maculopapular rash starting usually on the palms and soles then spreading throughout the body. 1, 30 Likewise, skin changes are the first phenotypic changes in our model, including a red rash starting from the limbs and spreading with ongoing GVHD over the whole body, combined with a strong scurfing and hair loss. In addition, histopathological skin features seen in GVHD bearing mice such as increased apoptosis and inflammatory infiltration 31 reflect histology of cutaneous biopsies obtained from patients. 30, 32, 33 Interestingly, in acute GVHD survivors we observe in late phase a sclerotic thickening of the skin which is also seen in patients developing chronic GHVD.
1 Accordingly, we found a time-dependent expansion of CD8+ T cells in the early acute phase and of CD4+ T cells in a late phase, suggesting the development of chronic skin GVHD in our mouse model.
We detected typical GVHD pathology in liver and intestines. 1, 30, 34, 35 Besides the main target organs, lymphoid organs, especially the thymus, are targeted during GVHD. In the preclinical model, we found impaired thymic function, which is in line with clinical observations on post-transplantation immune deficiency and thymic dysfunction. [36] [37] [38] Strong systemic inflammation included T-cell expansion along with a switch to an activated effector status of T cells. In addition, we detected delayed B-cell reconstitution during later stages of GVHD, which fits to clinical data demonstrating delayed B-cell recovery after HSCT. 39, 40 Cytokine dysregulation during GVHD has been described in patients and in MHC-mismatched mouse models.
14,41-43 However, it is well established that the degree of allo-mismatch and the intensity of conditioning influence the cytokine profile. 4 Different from MHC-mismatched mouse models, where TNF-α increases directly after TBI, 44 TNF-α cumulates later at the onset of acute GVHD around d+11 after BMT in our model. This compares with results obtained in patients where TNF-α levels only raised at later stages post HSCT. [45] [46] [47] [48] [49] The higher ability of TBI to induce a release of TNF-α, as compared with busulfan conditioning, may have contributed to these results. 50, 51 In conclusion, we believe that the use of chemotherapy-based, miHA-mismatched GVHD animal models may be a good option when studying clinically relevant questions in the field of allo-HSCT. However, future research has to investigate the efficiency of translating preclinical obtained results into the clinical setting.
